Abbott Laboratories <a href="https://www.reuters.com/markets/companies/ABT.N" target="_blank">(ABT.N)</a> said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatmen…